Marker Therapeutics Inc (MRKR)

[I Like Bottom Fishing]

TPIV — TapImmune, Inc. PinkSheets.com Company Profile:
Class Common Stock
Par Value: 0.001

Pink Quote/OTCBB
QuoteNewsChartsCompany InfoFilingsResearchShort InterestInsider Trans.

http://www.pinksheets.com/pink/quote/quote.jsp?symbol=tpiv#getCompanyInfo

http://www.tapimmune.com/

Inside QuoteBest Bid Best Ask Time of Last Inside Change
0.56 (2500 shares) 0.60 (2500 shares) 3:34 PM

Trade Data / Last Trade 3:32 PMLast Sale 0.60 Change +0.05
% Change +9.09 Tick Up
Daily High 0.60 Daily Low 0.54
Opening Price 0.60 Volume 56,556
52 wk. High 2.60 52 wk. Low 0.011
Prev Close 0.55 Dividend 0.00
Yield 0.00 Beta Coefficient 0.41
Earnings/Share -1.50 P/E Ratio
Trade data delayed 15 minutes.
Refresh All Data
OTC Disclosure & News ServiceSubscribe [The Pink OTC Markets RSS feed only includes news stories published via the OTC Disclosure and News Service.]

http://www.tapimmune.com/

Other News Sources
Pub Date Headline
Jan 12, 2010 TapImmune, Inc. Retains Wolfe Axelrod Weinberger Associates LLC as Its Investor Relations Counsel
Jan 12, 2010 www.StockMarketingInc.com: Dont Miss Out!! NUBL,ALTO,WSCE,IMOT,NVIC,TPIV:: Sign Up For Our Free Newsletter!!
Jan 11, 2010 www.StockMarketingInc.com: Dont Miss Out!! NUBL,ALTO,WSCE,IMOT,NVIC,TPIV:: Sign Up For Our Free Newsletter!!
Jan 11, 2010 TapImmune, Inc. to Present at OneMedPlace Forum 2010
Nov 25, 2009 TapImmune Announces Additional Funding
Nov 24, 2009 SectorWatch.biz: Vaccines Projected as Leading Pharma Growth Driver
Nov 23, 2009 TapImmune, Inc. to be Featured in Small Cap Stock Newsletter QualityStocks Daily
Nov 23, 2009 TapImmune, Inc. to be Featured in Small Cap Stock Newsletter QualityStocks Daily
Nov 5, 2009 TapImmune Signs License Agreement With Crucell N.V.
Nov 5, 2009 Stocks on the Move: TPIV, INO, MBCI, CRXL

http://www.tapimmune.com/

Contact Information Business Description
TapImmune, Inc.
800 Bellevue Way NE
Suite 400
Bellevue, WA 98004

http://www.tapimmune.com/

* Phone: [phone]

Cancer and viral disease immunotherapy products R&D company

*
OTC Market Tier
Pink Quote/OTCBB
*
Primary SIC — Industry Classification
2834 - Pharmaceutical preparations

*
State Of Incorporation
NV
*
Jurisdiction Of Incorporation
United States

*
Company Officers
Glynn Wilson, Executive Chairman
Denis Corin, Dir., President
Tracy A. Moore, CFO

*
SEC Reporting Status
SEC Reporting Company
*
CIK
0001094038
*
Fiscal Year End
12/31

*
Estimated Market Cap
$1,328,241 as of Jan 20, 2010
*
Outstanding Shares
2,414,983 as of Jul 27, 2009



*
Current Capital Change
shs decreased by 1 for 10 split
Pay Date: Jul 27, 2009

*
Company Notes
o Formerly=GeneMax Corp. until 6-07
o Formerly=Eduverse.com until 7-02
o Formerly=EDUVERSE Accelerated Learning Systems, Inc. until 6-99
o Formerly=Perfect Future, Ltd. until 6-98

*
Security Notes
o Capital Change=shs decreased by 1 for 50 split. Pay date=6-8-01
o Capital Change=shs decreased by 1 for 2.5 split Pay date=06/28/2007.

*
Transfer Agent
Holladay Stock Transfer
2939 N. 67th Place
Scottsdale, AZ 85251

http://www.tapimmune.com/

http://www.pinksheets.com/pink/quote/quote.jsp?symbol=tpiv#getCompanyInfo











The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases.
Click here to update your company profile.

TapImmune Inc. (otcbb: TPIV) Stock Symbol:Company Profile:
http://www.knobias.com/individual/public/quote.htm?ticker=TPIV
Knobias MEMBERS get: Quotes | Charts | Technical Analysis | Quick Profiles | EDGAR Filings | News & Alerts | TearSheet Profiles | Historical Statistics | Insider Transactions | Institutional Holdings | ...and Much More
http://www.knobias.com/individual/public/quote.htm?ticker=TPIV

http://www.tapimmune.com/

Download Printable Reports
Last Trade: 0.600 Change: 0.050 ( +9.091 %)
Previous Close: 0.550 Today's Open: 0.600
# of Trades: 19 Volume: 56,456
Avg. # of Trades: 104 Avg. Daily Volume: 160,121

Bid: 0.510 Bid Size: 2,500
Ask: 0.600 Ask Size: 2,500
Day High: 0.600 Day Low: 0.550
52 Week High: 2.600 52 Week Low: 0.011
Market Cap: 22.07M Dividend: N/A
EPS: N/A P/E Ratio: N/A

6 Month Chart

RAiDAR alerts Learn More About RAiDAR-LT
01/12/2010 (10:00 ET) TapImmune, Inc. Retains Wolfe Axelrod Weinberger Associates LLC as Its Investor Relations Counsel - GlobeNewswire
01/11/2010 (10:00 ET) TapImmune, Inc. to Present at OneMedPlace Forum 2010 - GlobeNewswire
01/06/2010 (17:02 ET) TPIV: Filed New Form PRE 14C, Preliminary Information Statement - Edgar
12/03/2009 (14:34 ET) TPIV: Filed New Form 8-K, Material Event Disclosure - Edgar
12/02/2009 (09:00 ET) Free Cash Flow for TapImmune Reaches Five Year Low - StockTrendNews.com
12/02/2009 (09:00 ET) StockDiagnostics.com Maintains a Suspended OPS Ranking on TapImmune - StockTrendNews.com
12/02/2009 (09:00 ET) TapImmune's Cash Flow from Operations Hits Five Year Low - StockTrendNews.com
11/30/2009 (12:12 ET) knobias pipe | LINE: Sparse PIPE Activity Surrounds Turkey Day - Knobias
11/25/2009 (15:04 ET) TPIV: Closes $600K PIPE; Units @ $0.80, Common + Warrants - Knobias
11/25/2009 (14:00 ET) TapImmune Announces Additional Funding - GlobeNewswire
11/23/2009 (09:00 ET) TapImmune, Inc. to be Featured in Small Cap Stock Newsletter QualityStocks Daily - Business Wire
11/16/2009 (16:05 ET) TPIV: Filed New Form 10-Q, Quarterly Report - Edgar
11/10/2009 (17:05 ET) TPIV: Filed New Form D - Edgar
11/10/2009 (17:02 ET) TPIV: Filed New Form D - Edgar
11/10/2009 (17:00 ET) TPIV: Filed New Form D - Edgar
11/05/2009 (09:00 ET) TapImmune Signs License Agreement With Crucell N.V. - GlobeNewswire
11/05/2009 (08:18 ET) Stocks on the Move: TPIV, INO, MBCI, CRXL - Market Wire
11/04/2009 (09:00 ET) TapImmune Signs License Agreement With Crucell N.V. - GlobeNewswire
10/26/2009 (16:50 ET) TPIV: New Form 4 Filed, Change in Beneficial Ownership - Edgar
10/26/2009 (16:38 ET) TPIV: New Form 4 Filed, Change in Beneficial Ownership - Edgar
10/26/2009 (11:25 ET) TPIV: Volume Spike; 22% > 20-adsv, Stock +8.20% - Knobias
10/16/2009 (18:19 ET) TPIV: New Form 4 Filed, Change in Beneficial Ownership - Edgar
10/16/2009 (13:51 ET) TPIV: Volume Spike; 62% > 20-adsv, Stock +20.75% - Knobias
10/07/2009 (10:55 ET) TPIV: Volume Spike; 13% > 20-adsv, Stock -13.71% - Knobias
10/07/2009 (09:30 ET) TapImmune Receives BUY Recommendation From the KonLin - GlobeNewswire

company profile
The Company focused on developing therapeutics to treat serious disorders, for cancer and infectious diseases. ... MORE INFO

CONTACT: Dr. Glynn Wilson, Ph.D. (CEO)
TapImmune Inc.
3590 West 41st Avenue
Unit 2
Vancouver, BC V6N 3E6
P: [phone]
P: [phone]
Company Home Page |

Industry: Drugs
SIC: 2836
Employees: 1
Locations: 1

State of Inc: NEVADA 2000
Development Stage? N Transfer Agent:
Holladay Stock Transfer
Scottsdale, AZ 85251

http://www.tapimmune.com/

Investor Relations:
Company Authorized Shares: 200,000,000
Source: 10QSB ( 03/31/2007 )

Outstanding Shares: 36,779,132
Source: MGFS ( 11/12/2009 )

Fiscal Year End: December 31

MANAGEMENT & INSIDERS:
Patrick A. McGowan, SEC/TR/CFO/DIR Alan Lindsay, DIR Denis Corin, PR/CEO
Glynn Wilson, DIR

Need More Stock Research? Subscribe NOW!!!

http://www.knobias.com/individual/public/quote.htm?ticker=TPIV











ABOUT | PARTNERS | ADVERTISING INFO | CONTACT US | COPYRIGHT | PRIVACY | LEGAL | DISCLAIMER
Copyright © 2010 Knobias.Com, LLC. All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Knobias.Com, LLC, nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Knobias.Com website(s), a user agrees not to redistribute the information found therein. Knobias.Com, LLC is not a registered broker-dealer and does not endorse or recommend any securities listed herein or any services of any brokerage company.

http://www.tapimmune.com/

TapImmune Inc. is a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease. The company’s lead product, the TAP vaccine performs a key step in moving characteristic markers called antigens to the surfaces of cells. Without TAP, there are no cancer markers, so the immune system fails to spot the rogue cells and the cancerous cells can grow undetected. The Company’s vaccine has shown effective restoration of TAP which restores and augments the marker (antigen) presentation and subsequent recognition and killing of cancer cells by the immune system. The TAP molecule also works as an adjuvant or ‘accelerant’ to enhance targeted vaccines against infectious diseases. Including TAP in the studied Smallpox Vaccine showed potency was increased by 100-1000 times. The company is currently developing AdhTAP for the commencement of toxicology studies leading to the initiation of Phase I clinical trials. The global vaccine market is expected to grow from $13 billion in 2007 to $21 billion in 2010.

The company’s technologies have been featured on ABC News BusinessNow, B-TV, in BusinessWeek, Popular Mechanics and local news papers as well as many respected medical journals including the Journal of Immunology, Nature (Biotechnology), International Journal of Cancer, Cancer Research and PLoS Pathogens among others.

http://www.tapimmune.com/